CyberKnife Dose Escalation Prostate Cancer Trial (CK-DESPOT)

  • End date
    Jul 12, 2028
  • participants needed
  • sponsor
    Crozer-Keystone Health System
Updated on 17 February 2022
bone scan
prostate specific antigen
stereotactic body radiation therapy
adenocarcinoma of prostate
prostate carcinoma


Stereotactic body radiation therapy (SBRT) has been employed in the treatment of prostate cancer. Multiple single institution experiences suggest high biochemical control rates with acceptable toxicity in low risk prostate cancer but efficacy data in unfavorable type prostate cancer is less convincing. CyberKnife-SBRT (CK-SBRT) can be used to escalate radiation dose delivery to the prostate while sparing normal tissue.


The optimal radiation schedule for the curative treatment of prostate cancer remains unknown. Prostate cancer patients receiving radiation therapy are typically treated 5 days per week for 8-9 weeks. Recent data suggest that large radiation fraction sizes are radio-biologically favorable over lower fraction sizes in prostate cancer radiotherapy. The sensitivity of a tumor or normal tissue to fraction size of radiation can be approximated by the alpha-beta ratio. It has been suggested that the alpha/beta ratio for prostate cancer is actually as low as 1.5 implying that the current radiation therapy paradigm for prostate cancer treatment might be fundamentally flawed, as high fraction sizes would be expected to damage tumor more readily.

Typical prostate SBRT doses do not appear to have similar efficacy in higher risk prostate cancer suggesting even higher doses are required. Many techniques including dose escalated external beam radiation therapy (EBRT), proton therapy (PT) and brachytherapy have been employed to increase dose to the prostate. Data from the ASCEND-RT trial utilizing low dose rate brachytherapy boost showed a dramatic 21% improvement in biochemical control at 9 years favoring brachytherapy boost compared to conventional dose escalated EBRT radiation therapy. However, no corresponding benefit was identified in overall survival, incidence of bone metastases or prostate cancer specific mortality while a 3 fold increase in late urinary toxicity was noted.

SBRT is well tolerated with minimal acute and late side effects. In this protocol, CK-SBRT will be used to target the microscopic and gross disease in the prostate, seminal vesicles. An escalated dose of 40 Gy in 5 fractions will be delivered to the entire target volume while any nodules visible within the prostate gland on endorectal MRI will receive 50 Gy in 5 fractions.

Condition Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Treatment CyberKnife SBRT
Clinical Study IdentifierNCT03822494
SponsorCrozer-Keystone Health System
Last Modified on17 February 2022


Yes No Not Sure

Inclusion Criteria

Histologically confirmed adenocarcinoma of the prostate diagnosed within 360 days of enrollment
Prostate Specific Antigen (PSA) documented within 90 days prior to registration
Clinical staging completed within 90 days of registration
No Nodal or Distant Metastases documented on CT or MRI of the pelvis and bone scan
Unfavorable Risk Prostate Carcinoma as Described is documented
No prior pelvic radiotherapy
No prior Trans-urethral resection of the prostate (TURP)
Prostate volume < 100 cc
American Urologic Association (AUA) score < 20
No recent (within 5 years) or concurrent cancers other than non-melanoma skin cancers
Patient must have no medical or psychiatric illnesses that would interfere with treatment or follow-up
No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery is allowed
Candidate for rectal spacer placement

Exclusion Criteria

Other cancer diagnosis other than non-melanoma skin cancer with 5 years
Prostate size greater than 100cc
AUA greater than 20
Implanted hardware impacting imaging
Metastatic prostate cancer
Contraindication to hormone therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note